Activity of essential phospholipids (EPL) from soybean in liver diseases

Pharmacological Reports

Volumn 63, Issue 3, 2011, Pages 643-659

  Gundermann, Karl Josef ^a   Kuenker, Ann ^b   Kuntz, Erwin ^c   Droździk, Marek ^a  

^a POMERANIAN MEDICAL UNIVERSITY   (Poland)

^b Elk Rapids Medical Clinic   (United States)

^c Scientific Institute of Hepatology   (Germany)

Author keywords

Chronic hepatitis; Essential phospholipids; Fatty liver; Fibrosis; Intoxication; Membrane therapy; Radicals

Indexed keywords

1,2 DILINOLEOYLPHOSPHATIDYLCHOLINE; ALPHA INTERFERON; ESSENTIALE; ETHAMBUTOL; ISONIAZID; MEVINOLIN; PEGINTERFERON; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PLACEBO; POLYENE PHOSPHATIDYLCHOLINE; PYRIDOXINE; RIBAVIRIN; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ALCOHOL LIVER CIRRHOSIS; ALCOHOL LIVER DISEASE; CELL PROTECTION; CHRONIC HEPATITIS; CHRONIC LIVER DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; FATTY LIVER; HEPATIC COMA; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER INJURY; LOW DRUG DOSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; SINGLE DRUG DOSE; SOYBEAN; TREATMENT OUTCOME; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT; VIRUS HEPATITIS;

EID: 80051530692     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(11)70576-X     Document Type: Review

References (159)

1. Aabdallah DM, Eid NI: Possible neuroprotective effects of lecithin and α-tocopherol alone or in combination against ischemia/reperfusion insult in rat brain. J Biochem Mol Toxicol, 2004, 18, 273-278. (Pubitemid 39463520)
2. Aleynik AI, Leo MA, Aleynik MK, Lieber CS: Polyenylphosphatidylcholine protects against alcohol but not iron-induced oxidative stress in the liver. Alcohol Clin Exp Res, 2000, 24, 196-206. (Pubitemid 30117422)
3. Aleynik MK, Leo MA, Aleynik SI, Lieber CS: Polyenylphosphatidylcholine opposes the increase of cytochrome P-450E1 by ethanol and corrects iron-induced decrease. Alcohol Clin Exp Res, 1999, 23, 96-100. (Pubitemid 29068471)
4. Aleynik MK, Lieber CS: Dilinoleoylphosphatidylcholine decreases ethanol-induced cytochrome P4502E1. Biochem Biophys Res Commun, 2001, 288, 1047-1051. (Pubitemid 33140991)
5. Aleynik SI, Leo MA, Aleynik MK, Lieber CS: Alcohol-induced pancreatic oxidative stress: protection by phospholipid repletion. Free Radic Biol Med, 1999, 26, 609-619. (Pubitemid 29146263)
6. Aleynik SI, Leo MA, Lieber CS: Polyenylphosphatidylcholine intake increases dilinoleolyphosphatidylcholine content and antioxidant capacity in human plasma. Hepatology, 2000, 25, Suppl, 544A.
7. Aleynik SI, Leo MA, Ma X, Aleynik MK, Lieber CS: Polyenylphosphatidylcholine prevents carbon tetrachloride-induced lipid peroxidation while it attenuates liver cirrhosis. J Hepatol, 1997, 27, 554-561. (Pubitemid 27390904)
8. Aleynik SI, Leo M-A, Takeshige U, Aleynik MK, Lieber CS: Dilinoleoylphosphatidylcholine is the active antioxidant of polyenyl- phosphatidylcholine. J Invest Med, 1999, 47, 507-512.
9. Aleynik SI, Lieber CS: Polyenylphosphatidylcholine corrects the alcohol-induced hepatic oxidative stress by restoring S-adenosylmethionine. Alcohol Alcohol, 2003, 38, 208-212. (Pubitemid 36582565)
10. Arvind N, Savaikar P, Rajkumar JS: Therapy for NAFLD - a comparative study of essential phospholipids vs. ursodeoxycholic acid. Ind J Clin Pract, 2006, 16, 21-24.
11. Baraona E, Zeballos GA, Shoichet L, Mak KM, Lieber CS: Ethanol consumption increases nitric oxide production in rats, and its peroxynitrite-mediated toxicity is attenuated by polyenylphosphatidylcholine. Alcohol Clin Exp Res, 2002, 26, 883-889. (Pubitemid 34666149)
12. Barbarino F, Neumann E, Toganel E, Stroila C, Gundermann KJ: Effect of "essential" phospholipids in experimental D-galactosamine-induced liver cell damage. Therapiewoche (Austria), 1990, 5, 415-419.
13. +-ATPase in cyclosporine A-treated rats. Dig Dis Sci, 1999, 44, 1643-1649.
14. 2+-ATPase and F-actin distribution in hepatocytes of cyclosporine A treated rats. Effect of soyabean lecithin and triacylglycerol. Cell Mol Biol, 1998, 44, 1221-1227.
15. Biagi PL, Bordoni A, Hrelia S, Celadon M, Turchetto E: The effect of dietary polyenylphosphatidylcholine on microsomal delta-6-desaturase activity, fatty acid composition, and microviscosity in the rat liver under oxidative stress. J Nutr Biochem, 1993, 4, 690-694. (Pubitemid 2019494)
16. Blikhar YM, Skakun NP: Essentiale in the therapy of chronic liver disease in patients with pulmonary tuberculosis (Russian). Probl Tuberk, 1988, 3, 41-44.
17. Brady LM, Fox ES, Fimmel CJ: Polyenylphosphatidylcholine inhibits PDGF-induced proliferation in rat hepatic stellate cells. Biochem Biophys Res Commun, 1998, 248, 4-179.
18. Brůha R, Mareček Z: Essentiale phospholipids in the treatment of hepatic encephalopathy (Czech). Vnitř Lék, 2000, 46, 199-204.
19. Buyeverov AO, Yeshanu VS, Mayevskaya MV, Ivashkin VT: Application of essential phospholipids in complex therapy of steatohepatitis of the mixed origin (Russian). Klin Persp Gastroenterol Hepatol, 2008, 1, 17-22.
20. Cantafora A, Masella R, Angelico M, Gandin C, Blount RJ, Peterson SW: Effect of intravenous polyunsaturated phosphatidylcholine infusion on insulin receptor processing and lipid composition in patients with liver cirrhosis. Eur J Clin Invest, 1992, 22, 777-782. (Pubitemid 23000185)
21. Cao Q, Mak KM, Lieber CS: Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-α generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun, 2002, 299, 459-464. (Pubitemid 35365651)
22. Cao Q, Mak KM, Lieber CS: Dilinoleoylphosphatidylcholine decreases LPS-induced TNF-α generation in Kupffer cells of ethanol-fed rats, respective roles of MAPKs and NF-κB. Biochem Biophys Res Commun, 2002, 294, 849-853. (Pubitemid 34687194)
23. Cao Q, Mak KM, Lieber CS: Dilinoleoylphosphatidylcholine prevents transforming growth factor β1-mediated collagen accumulation in cultured rat hepatic stellate cells. J Lab Clin Med, 2002, 139, 202-210. (Pubitemid 34557355)
24. Cao Q, Mak KM, Lieber CS: DLPC and SAMe combined prevent leptin-stimulated TIMP-1 production in LX-2 human hepatic stellate cells by inhibiting HO-mediated signal transduction. Liver Int, 2006, 26, 221-231.
25. Cao Q, Mak KM, Lieber CS: DLPC and SAME prevent α1(I) collagen mRNA up-regulation in human hepatic stellate cells, whether caused by leptin or menadione. Biochem Biophys Res Commun, 2006, 350, 50-55. (Pubitemid 44479860)
26. Cao Q, Mak KM, Lieber CS: DLPC decreases TGF-β1-induced collagen mRNA by inhibiting p38 MAPK in hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol, 2002, 283, G1051-G1061. (Pubitemid 35192841)
27. Chatterjee C, Young EK, Pussegoda KA, Twomey EE, Pandey NR, Sparks DL: Hepatic high-density lipoprotein secretion regulates the mobilization of cell-surface hepatic lipase. Biochemistry, 2009, 48, 5994-6001.
28. Chen Y, Hills BA, Hills YC: Unsaturated phosphatidylcholine and its application in surgical adhesion. ANZ J Surg, 2005, 1111-1114. (Pubitemid 43951375)
29. Chien S, Sung LP: Molecular basis of red cell membrane rheology. Part 1. Biorheology, 1990, 27, 327-344.
30. Chirkin AA, Konevalova NY, Grebennikov IN: Effect of polyunsaturated phosphatidylcholine on lipid transport system in alcoholic liver injury. Addiction Biol, 1998, 3, 65-70. (Pubitemid 28043853)
31. Chirkin AA, Konevalova NY, Grebennikov IN, Kulikov VA, Filipenko GV: Effect of polyunsaturated phosphatidylcholine on the activity of antioxidative and lipolytic enzymes in irradiated rats with alimentary hypercholesterolemia (Russian). Vopr Med Khim, 1994, 40, 24-28.
32. Cohen DE, Carey MC: Physical chemistry of biliary lipids during bile formation. Hepatology, 1990, 12, 143S-147S, discussion 147S-148S.
33. Cushley RJ, Okon M: NMR studies of lipoprotein structure. Annu Rev Biophys Biomol Struct, 2002, 31, 177-206. (Pubitemid 34666830)
34. Demirbilek S, Aydin G, Yücesan S, Vural H, Bitiren M: Polyunsaturated phosphatidylcholine lowers collagen deposition in a rat model of corrosive esophageal burn. Eur J Pediatr Surg, 2002, 12, 8-12. (Pubitemid 34279745)
35. Demirbilek S, Ersoy MO, Demirbilek S, Karaman A, Akin M, Bayraktar M, Bayraktar N: Effects of polyenylphosphatidylcholine on cytokines, nitrite/nitrate levels, antioxidant activity and lipid peroxidation in rats with sepsis. Intensive Care Med, 2004, 30, 1974-1978. (Pubitemid 39468423)
36. Demirbilek S, Gürses İ, Sezgin N, Karaman A, Gürbüz N: Protective effect of polyunsaturated phosphatidylcholine on stress ulcer formation in rats. J Pediatr Surg, 2004, 39, 57-62. (Pubitemid 38049837)
37. Demirbilek S, Karaman A, Baykarabulut A, Akin M, Gürünlü oglu K, Türkmen E, Taş E et al.: Polyenylphosphatidylcholine pre-treatment ameliorates ischemic acute renal injury in rats. Int J Urol, 2006, 13, 747-53. (Pubitemid 43926767)
38. Demirbilek S, Karaman A, Gürünlüoǧlu K, Taş E, Akin M, Aksoy RT, Türkmen E et al.: Polyenylphosphatidylcholine pre-treatment protects rat liver from ischemia/ reperfusion injury. Hepatol Res, 2006, 34, 84-91. (Pubitemid 43137556)
39. Desreumaux C, Dedonder E, Dewailly P, Sézille G, Furchart JC: Effects of unsaturated fatty acids in phospholipids on the in vitro activation of the lipoprotein lipase and the triglyceride lipase. Drug Res, 1979, 29, 1581-1583. (Pubitemid 10231713)
40. Dinakaran N: Safety and efficacy of Essentiale-L on the treatment of non-alcoholic fatty liver disease. Indian J Clin Practice, 2003, 14, 51-58.
41. Feng Zh, Shen Zh, Tan SH, Qi Ch: Prevention and treatment on alcoholic fatty liver by Essentiale (Chinese). Chin J Gastro Hepa, 2005, 14, 480-486.
42. Fomina TI, Vetoshkina TV, Dibskaya TY: Pharmacological corrections of platidiam hepatotoxic effect (Russian). Eksp Klin Farmakol, 1999, 62, 62-64.
43. Ghose N, Santra A, Pal A, Mazumdar DN: Role of essential phospholipids (EPL) in acute viral hepatitis. Indian Med Gazette, 1993, 6, 179-183.
44. Gonciarz Z, Besser P, Lelek E, Gundermann K-J, Johannes K-J: Randomized placebo-controlled double-blind trial on "essential" phospholipids in the treatment of fatty liver associated with diabetes. Méd Chir Dig, 1988, 17, 61-65.
45. Gryshchenko VA, Lytvynenko ON: Peculiarities of the bilious acid spectrum of bile and duodenal content in mice at medicamentous hepatitis and use of correction therapy (Ukrainian). Ukr Biokhim Zh, 2007, 79, 97-101. (Pubitemid 350183832)
46. Gubsky VI, Radzinsky VO: Effects of the antioxidants alpha-tocopherol and Essentiale on protein biosynthesis in the chemically damaged liver and placenta (Russian). Farm Zh, 1998, 4, 72-73.
47. Gundermann K-J, Lehmacher W: The essential phospholipids as liver therapeutic - a meta-analysis of double-blind trials in chronic liver disease (Polish). Gastroenterol Pol, 1998, 5, 553-539.
48. Gundermann K-J: The "Essential" Phospholipids as a Membrane Therapeutic. Szczecin, Jota Press, 1993.
49. Gurevich V, Bondarenko B, Gundermann K-J: Polyunsaturated phospholipids increase the hypolipidemic effect of lovastatin. Eur J Int Med, 1997, 8, 13-18.
50. Hills BA: Role of surfactant in peritoneal dialysis. Perit Dial Int 2000, 20, 503-515.
51. Yano M, Koga M, Shirahama S, Toda T, Ohta Y, Hirayama C: Blind assessment of liver biopsy findings in chronic hepatitis: drug efficacy trial of polyenephosphatidylcholine (Japanese). Shindan to chiryô, 1978, 9, 1783-1789.
52. Holeček M, Mráz J, Koldová P: "Essential" phospholipids stimulate liver regeneration after 70% hepatectomy and after carbon tetrachloride induced liver damage. Prog Hepato-Pharmacol, 1995, 1, 202-212.
53. Hu G, Liu K, Zhao L: Polyunsaturated phosphatidylcholine (Essentiale) in the treatment of alcoholic liver disease and fatty liver disease, a systematic review (Chinese). Liver, 2005, 10, 5-7.
54. Hu G-P, Liu K, Wang S, Tang H, Zhao L-S: Polyunsaturated phosphatidylcholine (Essentiale) for chronic hepatitis, a systematic review (Chinese). Chin J Evidence- Based Med, 2005, 5, 543-548.
55. Huber R, Futter I, Lüdtke R: Oral silymarin for chronic hepatitis C - a retrospective analysis comparing three dose regimens. Eur J Med Res, 2005, 10, 6870.
56. Ilič V, Begic-Janeva A: Treatment of HBsAg positive chronic active hepatitis. Efficacy of "essential" phospholipids (German). Med Welt, 1991, 42, 523-525.
57. Ilič V, Kordač V, Alvarez SZ: Clinical experience with long-term administration of "essential" phospholipids in chronic active hepatitis. Review of 3 double-blind studies (Czech). Cas Lék Čes, 1992, 131, 801-804. (Pubitemid 23030264)
58. Indovina I, Licata G, Scaglione R, Parrinello G: Effect of i.v. administered polyunsaturated phosphatidylcholine (EPL) in hepatopathies. Study on morphology and function of 99mTc parabutyl-IDA (Italian). Epatologica, 1981, 27, 261-278. (Pubitemid 12208046)
59. Jayaraman T, Kannappan S, Ravichandran MK, Anuradha CV: Impact of Essentiale L on ethanol-induced changes in rat brain and erythrocytes. Singapore Med J, 2008, 49, 320-327. (Pubitemid 351716740)
60. Jenkins PJ, Portmann BP, Eddleston ALWF, Williams R: Use of polyunsaturated phosphatidylcholine in HBsAg negative chronic active hepatitis, results of prospective double-blind controlled trial. Liver, 1982, 2, 77-81. (Pubitemid 12037184)
61. Kanmaz T, Karakayali H, Sakallioglu AE, Ozdemir BH, Haberal M: Polyunsaturated phosphatidylcholine protects against wound contraction in experimental skin burn injury. J Invest Surg, 2004, 17, 15-22. (Pubitemid 38313052)
62. Karachunsky MA, Adamovich NV, Abdullayev AA : Specific features of chemotherapy of pulmonary tuberculosis and its effectiveness in diabetes mellitus patients (Russian). Probl Tuberk, 1991, 5, 31-33.
63. Karaman A, Demirbilek S, Sezgin N, Gürbüz N, Gürses İ: Protective effect of polyunsaturated phosphatidylcholine on liver damage induced by biliary obstruction in rats. J Pediatr Surg, 2003, 38, 1341-1347. (Pubitemid 37159085)
64. Katz GG, Shear NH, Malkiewicz IM, Valentino K, Neumann MG: Signalling for ethanol-induced apoptosis and repair in vitro. Clin Biochem, 2001, 34, 219-227. (Pubitemid 32537674)
65. Kharchenko NV, Korulya IA: Efficacy and tolerability of Essentiale forte N preparation in the treatment of patients with non-alcoholic steatohepatitis (Ukrainian). Such Gastroenterol, 2004, 19, 46-49.
66. Klinger W, Müller D, Kleeberg U, Kretzschmar M, Splinter FK: The influence of "essential" phospholipids (EPL) on phase-I- and phase-II-reactions and on the glutathione status in the liver of aging rats. Exp Pathol, 1991, 41, 151-156.
67. Knauff HG, Georgii A, Matzen K: Influence of choline phospholipids on the spectrum of free plasma amino acids of toxic liver damage (German). Klin Wochenschr, 1963, 41, 915-919.
68. Knüchel F: Double-blind study in patients with alcoholic fatty liver (German). Med Welt, 1979, 30, 411-416.
69. Konoplia YN, Prokopenko LG: Essentiale as immunomodulator in toxic liver damage (Russian). Eksp Klin Farmakol, 1992, 2, 5-8.
70. Kordač V, Brodanová M, Marecek Z, Jirásek A: Essentiale® forte in the treatment of chronic active hepatitis (Czech). Prakt Lék (Praha), 1985, 65, 834-837.
71. Kowala-Piaskowska A, Mozer-Lisewska I, Służewski W, Bujnowska A: Intravenous administration of essential phospholipids for the treatment of acute and chronic viral hepatitis in children (Polish). Klin Ped, 1999, 7, 425-429.
72. Kožurková M, Mišúrová E, Kropáčová K, Haková H: The effect of Essentiale on histones and nucleic acids in liver and blood-forming tissues of rats irradiated with γ-rays. Radiats Biol Radioecol, 1999, 39, 388-393.
73. Kropáčová K, Mišúrová E: The influence of essential phospholipids (ESSENTIALE) on liver regeneration in gamma irradiated rats. Physiol Res, 1995, 44, 241-247.
74. Kuntz E: Pilot study with polyenylphosphatidylcholine in severe liver insufficiency (German). Med Welt, 1989, 40, 1327-1329.
75. Kuntz E: The "essential" phospholipids in hepatology -50 years of experimental and clinical experiences (German). Z Gastroenterol, 1991, 29, Suppl 2, 7-13.
76. Kuntz E: The "essential" phospholipids in hepatology - experimental and clinical experiences. Prog Hepato-Pharmacol, 1995, 1, 156-167.
77. Lazareva GA, Brovkina IL: Protective effect of biological oxidation activators in nitrite intoxication of rats (Russian). Antibiot Khimioter, 2005, 50, 8-12. (Pubitemid 44077104)
78. Lazareva GA, Brovkina IL: The protective action of Essentiale, Riboxin, and Elkar against hemotoxic anemia (Russian). Eksp Klin Farmakol, 2006, 69, 48-51. (Pubitemid 43892329)
79. Lee SH, Han YM, Min BH, Park IS: Cytoprotective effects of polyenoylphosphatidylcholine (PPC) on β-cells during diabetic induction by streptozotocin. J Histochem Cytochem, 2003, 51, 1005-1015.
80. LeKim D, Graf E: Animal experimental studies on the pharmacokinetics of "essential" phospholipids (German). Drug Res, 1976, 26, 1772-1782.
81. Levy C, Seeff LD, Lindor KD: Use of herbal supplements for chronic liver disease. Clin Gastroenterol Hepatol, 2004, 2, 947-956. (Pubitemid 39539743)
82. Li J, Kim C-I, Leo MA, Mak KM, Rojkind M, Lieber CS : Polyunsaturated lecithin prevents acetaldehyde-mediated hepatic collagen accumulation by stimulating collagenase activity in cultured lipocytes. Hepatology, 1992, 16, 373-381.
83. Li J-H, Chen X-Y, Zhong C-F, Min J: A randomized controlled study of essential phospholipids (Essentiale capsules) in the treatment of fatty liver (Chinese). Infect Dis Information, 2000, 13, 180-181.
84. Lieber CS: New concepts of the pathogenesis of alcoholic liver disease lead to novel treatments. Curr Gastroenterol Rep, 2004, 6, 60-65.
85. Lieber CS: Prevention and treatment of liver fibrosis based on pathogenesis. Alcohol Clin Exp Res, 1999, 23, 944-949.
86. Lieber CS, Anand BS, Bibi EJ: Polyenylphosphatidylcholine (PPC) is beneficial for the treatment of hepatitis C. Hepatology, 2005, 42, Suppl 1, 695A.
87. Lieber CS, DeCarli LM, Mak KM, Kim C-I, Leo MA: Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology, 1990, 12, 1390-1398.
88. Lieber CS, Leo MA, Aleynik SI, Aleynik MK, DeCarli LM: Polyenylphosphatidylcholine decreases alcohol-induced oxidative stress in the baboon. Alcohol Clin Exp Res, 1997, 21, 375-379. (Pubitemid 27176292)
89. Lieber CS, Robins SJ, Leo MA: Hepatic phosphatidylethanolamine methyltransferase activity is decreased by ethanol and increased by phosphatidylcholine. Alcohol Clin Exp Res, 1994, 18, 592-595. (Pubitemid 24189283)
90. Lieber CS, Robins SJ, Li J, DeCarli LM, Mak KM, Fasulo JM, Leo MA: Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology, 1994, 106, 152-159. (Pubitemid 24011876)
91. Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S: II. Veterans affairs cooperative study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res, 2003, 27, 1765-1772. (Pubitemid 37444363)
92. Liu E: The curative effect observation of Essentiale on treating severe jaundice type of hepatitis (Chinese). Mod J Integr Trad Chin West Med, 2003, 12, 402.
93. Ma X, Zhao J, Lieber CS: Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. J Hepatol, 1996, 24, 604-613. (Pubitemid 26168640)
94. Magomedov S, Shipulin VP: Serum metabolism of the connective tissue in patients with chronic hepatitis C (Russian). Such Gastroenterol, 2001, 2, 50-53.
95. Mak KM, Wen K, Ren C, Lieber CS: Dilinoleoylphosphatidylcholine reproduces the antiapoptotic actions of polyenylphosphatidylcholine against ethanol-induced hepatocyte apoptosis. Alcohol Clin Exp Res, 2003, 27, 997-1005. Erratum in, Alcohol Clin Exp Res, 2003, 27, 1212. (Pubitemid 36890402)
96. Maneesh M, Jayalekshmi H, Dutta S, Chakrabarti A, Vasudevan DM: Effect of exogenous lecithin on ethanol-induced testicular injuries in Wistar rats. Indian J Physiol Pharmacol, 2005, 49, 297-304. (Pubitemid 41059920)
97. Marpaung B, Tarigan P, Zein LH, Barus AP, Soekiman I: Tuberculostatic combination treatment with INH/RMP/EMB and administration of Essentiale forte for the prevention of liver damage (German). Therapiewoche, 1988, 38, 734-740.
98. Mastellone I, Polichetti E, Grès S: Dietary soybean phosphatidylcholine lowers lipidemia. Mechanisms at the levels of intestine, endothelial cell, and hepatobiliary axis. J Nutr Biochem, 2000, 11, 461-466.
99. Mathur SN, Simon I, Lokesh BR, Spector AA: Phospholipid fatty acid modification of rat liver microsomes affects acylcoenzyme A: cholesterol acyltransferase activity. Biochim Biophys Acta, 1983, 751, 401-411. (Pubitemid 13095029)
100. Mi L-J, Mak KM, Lieber CS: Attenuation of alcohol-induced apoptosis of hepatocytes in rat livers by polyenylphosphatidylcholine (PPC). Alcohol Clin Exp Res, 2000, 24, 207-212. (Pubitemid 30117423)
101. Minto RE, Adhikari PR, Lorigan GA: A 2H solid-state NMR spectroscopic investigation of biomimetic bicelles containing cholesterol and polyunsaturated phosphatidylcholine. Chem Phys Lipids, 2004, 132, 55-64. (Pubitemid 39458320)
102. Mourelle M, Guarner F, Malagelada JR: Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology, 1996, 110, 1093-1097. (Pubitemid 26113749)
103. Müting D, Dohn P, Reikowski J: The action of intravenous and oral administration of high doses of "essential"phospholipids on protein and lipid metabolism and on enzyme activity in chronic liver disease (German). Verh Dtsch Ges Inn Med, 1972, 78, 1389-1392.
104. Navder KP, Baraona E, Leo MA, Lieber CS: Oxidation of LDL in baboons is increased by alcohol and attenuated by polyenylphosphatidylcholine. J Lipid Res, 1999, 40, 983-987. (Pubitemid 29287868)
105. Navder KP, Baraona E, Lieber CS: Polyenylphosphatidylcholine attenuates alcohol-induced fatty liver and hyperlipemia in rats. J Nutr, 1997, 127, 1800-1806. (Pubitemid 27386407)
106. Navder KP, Baraona E, Lieber CS: Polyenylphosphatidylcholine decreases alcoholic hyperlipemia without affecting the alcohol-induced rise of HDL cholesterol. Life Sci, 1997, 61, 1907-1914. (Pubitemid 27461523)
107. Navder KP, Lieber CS: Dilinoleoylphosphatidylcholine is responsible for the beneficial effects of polyenylphosphatidylcholine on ethanol-induced mitochondrial injury in rats. Biochem Biophys Res Commun, 2002, 291, 1109-1112. (Pubitemid 34694388)
108. Neuberger J, Hegarty JE, Eddleston ALWF, Williams R: Effect of polyunsaturated phosphatidylcholine on immune mediated hepatocyte damage. Gut, 1983, 24, 751-755. (Pubitemid 13030242)
109. Niederau C, Strohmeyer G, Heintges T, Peter K, Göpfert E: Polyunsaturated phosphatidyl-choline and interferon alpha for treatment of chronic hepatitis B and C. A multicenter, randomized, double-blind, placebo-controlled trial. Hepato-Gastroenterol, 1998, 45, 797-804. (Pubitemid 28321061)
110. Oette K, Kühn G, Römer A, Niemann R, Gundermann KJ, Schumacher R: The absorption of dilinoleoylphosphatidylcholine after oral administration (German). Drug Res, 1995, 45, 875-879.
111. Ohbayashi H, Fujimoto M, Yamase H, Ito M: Improvement of NASH with oral polyenephosphatidylcholine. J Rural Med, 2007, 1, 67-73.
112. Ohbayashi H, Fujimoto M, Yoshida M, Ito M, Yamase H: The therapeutic effect of polyenephosphatidylcholine (EPL) on NASH (Japanese). Liver, Bile and Pancreas, 2006, 52, 637-642.
113. Okiyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ, Aoyama T: Polyenylphosphatidylcholine prevents alcoholic liver disease in PPARα-null mice though attenuation of increases in oxidative stress. J Hepatol, 2009, 50, 1236-46.
114. Oneta CM, Mak KM, Lieber CS: Dilinoleoylphosphatidylcholine selectively modulates lipopolysaccharide-induced Kupffer cell activation. J Lab Clin Med, 1999, 134, 466-470. (Pubitemid 29530695)
115. Ortenberg EA, Tazhudinova SJ: Comparative study of the efficacy of certain hepatoprotective agents in liver damage caused by combined ethanol and tuberculostatic drugs (Russian). Farmakol Toksikol, 1984, 471, 102-105. (Pubitemid 14091285)
116. Panda RS, Patel DK: Polyunsaturated phosphatidylcholine (EPL, Essentiale) in viral hepatitis. Indian Pract, 1994, 47, 751-756.
117. Pandey NR, Renwick J, Misquith A, Sokoll K, Sparks DL: Linoleic acid-enriched phospholipids act through peroxisome proliferator-activated receptors α to stimulate hepatic apolipoprotein A-I secretion. Biochemistry, 2008, 47, 1579-1587. (Pubitemid 351231208)
118. Panos MZ, Polson R, Johnson R, Portmann B, Williams R: Polyunsaturated phosphatidyl choline for acute alcoholic hepatitis, a double-blind, randomized, placebo-controlled trial. Eur J Gastroenterol Hepatol, 1990, 2, 351-355. (Pubitemid 20384083)
119. Perederiy VG, Babak OY, Zadorozhna TD: Should patients with chronic hepatitis C and without indication to α-interferon therapy be treated? (Russian). Such Gastroenterol, 2001, 1, 60-63.
120. Petera V, Prokop V: The compensated cirrhosis of the liver (German). Therapiewoche, 1986, 36, 540-544.
121. Polichetti E, Janisson A, Iovanna C: Stimulation of the apo AI-high density lipoprotein system by dietary soyabean lecithin in humans. J Nutr Biochem, 1998, 9, 659-664. (Pubitemid 28498198)
122. Polichetti E, Janisson A, Lechène de la Porte P, Portugal H, Léonardi J, Luna A, La Droitte P et al.: Dietary polyenylphosphatidylcholine decreases cholesterolemia in hypercholesterolemic rats, role of the hepato-biliary axis. Life Sci, 2000, 67, 2563-2576.
123. Poniachik J, Baraona E, Zhao J, Lieber CS: Dilinoleoylphosphatidylcholine decreases hepatic stellate cell activation. J Lab Clin Med, 1999, 133, 342-348. (Pubitemid 29373031)
124. Rambaldi A, Gluud C: S-adenosyl-L-methionine for alcoholic liver diseases. Cochrane Database Syst Rev, 2006, 2, CD002235.
125. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C: Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol, 2005, 100, 2583-2591.
126. Sakakima Y, Hayakawa A, Nagasaka T, Nakao A: Prevention of hepatocarcinogenesis with phosphatidylcholine and menaquinone-4, in vitro and in vivo experiments. J Hepatol, 2007, 47, 83-92. (Pubitemid 46817686)
127. Sakakima Y, Hayakawa A, Nakao A: Phosphatidylcholine induces growth inhibition of hepatic cancer by apoptosis via death ligands. Hepato-Gastroenterol, 2009, 56, 481-484.
128. Salvioli G, Pula B, Pradelli JM: Variation of membrane composition during EPL feeding. Prog Hepato-Pharmacol, 1995, 1, 191-201.
129. Salvioli G. The effect of EPL administration in liver cirrhosis. Z Gastroenterol, 1991, 29, Suppl 2, 30-33.
130. Saratikov AS, Vengerovskii AI, Mozzhelin ME, Sukhodolo IV: The effect of hepatoprotectors containing phospholipids on rats with experimental acute pancreatitis (Russian). Eksp Klin Farmakol, 2004, 67, 35-37. (Pubitemid 39303459)
131. Saratikov AS, Vengerovskii AI, Sedykh IM: Effect of hepatoprotective drugs on the liver structural and metabolic disturbances in D-galactosamine- induced intoxication (Russian). Farmakol Toksikol, 1990, 53, 38-40. (Pubitemid 20101357)
132. Schüller-Peréz A, González-San Martin F: Placebo-controlled study with polyunsaturated phosphatidylcholine in alcoholic steatosis of the liver (German). Med Welt, 1985, 36, 517-521.
133. Seifulla NR, Kovalev IE, Rozhkova EA, Panyushkin VV: Effect of Carnosine and its combination with Essentiale on lipid peroxidation and work capacity of experimental animals (Russian). Eksp Klin Farmakol, 2005, 68, 44-46. (Pubitemid 41564985)
134. Shalina RI, Kusch IB, Oreshkina VP, Azizova OA, Kozlov AV, Panasenko OM: Antioxidants as a part of combined treatment of patients with late gestosis (Russian). Akush Ginekol, 1989, 65, 37-41. (Pubitemid 19146553)
135. Shaw D, Leon C, Kolev S, Murray V: Traditional remedies and food supplements. A five year toxicological study (1991-1995). Drug Saf, 1997, 17, 342-356. (Pubitemid 27496853)
136. Singh AK, Jiang Y, Benlhabib E, Gupta Sh: Herbal mixtures consisting of puerarin and either polyenylphosphatidylcholine or curcumin provide comprehensive protection against alcohol-related disorders in P rats receiving free choice water and 15% ethanol in pure water. J Med Food, 2007, 10, 526-42.
137. Singh NK, Prasad RC: A pilot study of polyunsaturated phosphatidylcholine in fulminant and subacute hepatic failure. JAPI, 1998, 46, 530-532.
138. Skakun NP, Klimnyuk EV: Experimental pharmacotherapy of indomethacin-induced lesions of the liver (Russian). Farmakol Toksikol, 1990, 53, 52-54.
139. Son Y, Lee JH, Kim N-H, Surh N-Y, Kim E-Ch, Chung H-T, Kang DG, Pae H-O: Dilinoleoylphosphatidylcholine induces the expression of the anti-inflammatory heme oxygenase-1 in RAW264.7 macrophages. Biofactors, 2010, 36, 210-215.
140. Tanamly MD, Tadros F, Labeeb S, Makld H, Shehata M, Mikhail N, Abdel-Hamid M et al.: Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village, study description and 12-month results. Dig Liv Dis, 2004, 36, 752-759. (Pubitemid 41070597)
141. Théret CG, Alliet J, Comlan G, Köbele H, Gourdier D: Hepatic steatosis in the malnourished child - protective and curative effects of phosphatidylcholine with highly unsaturated fatty acids, demonstrated with the ultrastructures of 66 biopsies (French). L'Ouest Méd, 1977, 22, 1595-1614.
142. Uteshev BS, Baiburin FY, Prokopenko LG: Immunomodulating and antioxidant effect of β-carotene and Essentiale in disturbed lipid metabolism (Russian). Eksp Klin Farmakol, 1998, 61, 41-44.
143. Veldhuizen R, Nag K, Orgeig S, Possmayer F: The role of lipids in pulmonary surfactant. Biochim Biophys Acta, 1998, 1408, 90-108. (Pubitemid 28517860)
144. Vengerovskii AI, Baturina NO, Chuchalin VS, Saratikov AS: Role of lipid peroxidation in the mechanism of hepatic fibrosis tissue proliferation in experimental chronic hepatitis (Russian). Patol Fiziol Eksp Ter, 1996, 40, 37-39.
145. Vengerovskii AI, Ogorodova LM, Perevozchikova TV: Hepatoprotectors containing phospholipids decrease the immunosuppressive effect of prednisolone in rats with experimental toxic hepatitis (Russian). Eksp Klin Farmakol, 2004, 67, 50-53. (Pubitemid 39303464)
146. Verma S, Thuluvath PJ: Complementary and alternative medicine in hepatology, review of the evidence of efficacy. Clin Gastroenterol Hepatol, 2007, 5, 408-416. (Pubitemid 46575355)
147. Visco G: Polyunsaturated phosphatidylcholine (EPL) in association with vitamin B complex for the treatment of acute viral hepatitis B. Results of a randomized double-blind clinical study (Italian). Clin Ter, 1985, 114, 183-188.
148. Vorobjov PA, Avksentieva MV, Sidorova LV, Kuligina YA, Sura MV, Tyurina IV: A clinical-economic study of the application of Essentiale H preparation in the combination with interferon in patients having chronic viral hepatitis B and C infection (Russian). Biull Clin-Econ Analysis. In: The Problems of Standardization in Public Health (Russian), 2004, 3, 57-62.
149. Wang BE, Li JH, Lin SR, Min J, Zhang LX, Li JH: The multicentre randomized double-blind controlled clinic trial of Essentiale for chronic viral hepatitis. The final report. Research Report 2000.
150. White DA: The phospholipid composition of mammalian tissues. In: Form and Function of Phospholipids. Eds. Ansell GB, Hawthorne JN, Dawson RMC, Elsevier, Amsterdam-London-New York, 1973, 441-482.
151. Wojcicki J, Dutkiewicz T, Gieldanowski J, Samochowiec L, Barcew-Wiszniewska B, Rózewicka L, Wira D et al.: Essential phospholipids (EPL) modify immunological functions and reduce experimental atherosclerosis in rabbits. Atherosclerosis, 1992, 93, 7-16.
152. Xian C, Tang X, Xiao Z: Essentiale solution for injection in fulminant hepatitis. Research Report 1992
153. Xu Y, Leo MA, Lieber CS: DLPC attenuates alcohol-induced cytotoxicity in
154. Zamaria N: Alteration of polyunsaturated fatty acid status and metabolism in health and disease. Reprod Nutr Dev, 2004, 44, 273-282.
155. Zhang X, Gundermann K-J, Wu S: Therapeutic effect of polyene phosphatidylcholine compound in chronic active hepatitis B (Chinese). Chin J Pharmacoepidemiol, 1995, 4, 4-6.
156. Zierenberg O, Assmann G, Schmitz G, Rosseneu M: Effect of polyenephosphatidylcholine on cholesterol uptake by human high density lipoprotein. Atherosclerosis, 1981, 39, 527-542. (Pubitemid 11071750)
157. Zierenberg O, Grundy SM: Intestinal absorption of polyenephosphatidylcholine in man. J Lipid Res, 1982, 23, 1136-1142. (Pubitemid 13187609)
158. Zierenberg O, Odenthal J, Betzing H: Incorporation of PPC into serum lipoproteins after oral or i.v. administration. Atherosclerosis, 1979, 34, 259-276. (Pubitemid 10209105)
159. Zverinsky IV, Karpovich VE, Bushma MI: The effect of Essentiale and its combination with cordiamin and vitamin E on the processes of xenobiotic biotransformation, lipid peroxidation, and structure of the liver in rats with cholestasis (Russian). Eksp Klin Farmakol, 1998, 61, 33-36.